Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: A retrospective review

Clinical Therapeutics

Volumn 31, Issue 6, 2009, Pages 1209-1218

  Snider, Melissa ^a   Kalbfleisch, Steven ^a   Carnes, Cynthia A ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

adverse effects; antiarrhythmic drug; drug interactions; monitoring; pharmacotherapy

Indexed keywords

ALFUZOSIN; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AZITHROMYCIN; CIMETIDINE; CRATAEGUS EXTRACT; DIGOXIN; DOFETILIDE; HERBACEOUS AGENT; LEVOFLOXACIN; POTASSIUM; PROPAFENONE; QUETIAPINE; RISPERIDONE; SIMVASTATIN; SOTALOL; TIZANIDINE; VENLAFAXINE;

ABNORMAL LABORATORY RESULT; ARTICLE; CLINICAL PHARMACY; CLINICAL PROTOCOL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HOSPITAL DISCHARGE; HUMAN; LABORATORY TEST; LUNG DISEASE; LUNG FUNCTION TEST; MEDICAL SPECIALIST; NURSE; OUTPATIENT CARE; PATIENT COMPLIANCE; PHARMACIST; PHYSICIAN; QT PROLONGATION; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY;

AGED; AMBULATORY CARE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CONTINUITY OF PATIENT CARE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACISTS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL ROLE; RETROSPECTIVE STUDIES;

EID: 68749098708     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.014     Document Type: Article

References (17)

1. Zipes D.P., Camm A.J., Borggrefe M., et al., the American College of Cardiology/American Heart Association Task Force, the European Society of Cardiology Committee for Practice Guidelines, the European Heart Rhythm Association, the Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 114 (2006) e385-e484
2. Blomström-Lundqvist C., Schein-man M.M., Aliot E.M., et al., the American College of Cardiology, the American Heart Association Task Force on Practice Guidelines, the European Society of Cardiology Committee for Practice Guidelines, the Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias. ACC/AHA/ ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias). Circulation. 108 (2003) 1871-1909
3. Fuster V., Rydén L.E., Cannom D.S., et al., the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, the European Society of Cardiology Committee for Practice Guidelines, the European Heart Rhythm Association, the Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published correction appears in Circulation. 2007;116: e138]. Circulation. 114 (2006) e257-e354
4. Goldschlager N., Epstein A.E., Nac-carelli G.V., et al., the Practice Guidelines Subcommittee and the North American Society of Pacing and Electrophysiology (HRS), the North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone: 2007 [published correction appears in Heart Rhythm. 2007;4:1590]. Heart Rhythm. 4 (2007) 1250-1259
5. Tran A., Vichiendilokkul A., Racine E., and Milad A. Practical approach to the use and monitoring of dofetilide therapy. Am J Health Syst Pharm. 58 (2001) 2050-2059
6. Stelfox H.T., Ahmed S.B., Fiskio J., and Bates D.W. Monitoring amiodarone's tox-icities: Recommendations, evidence, and clinical practice. Clin Pharmacol Ther. 75 (2004) 110-122
7. Bickford C.L., and Spencer A.P. Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm. 12 (2006) 254-259
8. Burgess C., Blaikie A., Ingham T., et al. Monitoring the use of amio- darone: Compliance with guidelines. Intern Med J. 36 (2006) 289-293
9. Raebel M.A., Carroll N.M., Simon S.R., et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm. 12 (2006) 656-664
10. Sanoski C.A., Schoen M.D., Gonzalez R.C., et al. Rationale, development, and clinical outcomes of a multidis-ciplinary amiodarone clinic. Pharmacotherapy. 18 (1998) 146S-151S
11. Goldschlager N., Epstein A.E., Nac-carelli G., et al., the Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med. 160 (2000) 1741-1748
12. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16 (1976) 31-41
13. Blouin R.A., Mann H.J., Griffen Jr. W.O., et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther. 26 (1979) 508-512
14. Bauer L.A., Blouin R.A., Griffen Jr. W.O., et al. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm. 37 (1980) 519-522
15. Thomson Reuters Healthcare. Micromedex Web site. http://www.micromedex.com Accessed June 12, 2009
16. QT drug lists; drug-drug interactions; drug-induced arrhythmias registry. Arizona CERT Web site. http://www.azcert.org/index.cfm Accessed June 12, 2009
17. Rigelsky J.M., and Sweet B.V. Hawthorn: Pharmacology and therapeutic uses. Am J Health Syst Pharm. 59 (2002) 417-422